ZD4054 Zibotentan + Paclitaxel + Carboplatin + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
Conditions
Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
Trial Timeline
Jun 1, 2009 → Jun 1, 2011
NCT ID
NCT00929162About ZD4054 Zibotentan + Paclitaxel + Carboplatin + Placebo
ZD4054 Zibotentan + Paclitaxel + Carboplatin + Placebo is a phase 2 stage product being developed by AstraZeneca for Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy. The current trial status is terminated. This product is registered under clinical trial identifier NCT00929162. Target conditions include Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00929162 | Phase 2 | Terminated |
Competing Products
20 competing products in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + Epoetin beta | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 + R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| R744 | Chugai Pharmaceutical | Phase 3 | 77 |
| PLX3397 + Temozolomide | Daiichi Sankyo | Phase 1/2 | 41 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| Roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| ASP8825 | Astellas Pharma | Phase 1 | 33 |
| ASP015K | Astellas Pharma | Phase 1 | 33 |
| ASP7991 | Astellas Pharma | Phase 1 | 33 |
| Roxadustat + Epoetin Alfa | Astellas Pharma | Phase 3 | 77 |
| ATG-F | Astellas Pharma | Approved | 85 |
| Celecoxib | Astellas Pharma | Pre-clinical | 23 |
| roxadustat + Darbepoetin alfa | Astellas Pharma | Phase 3 | 77 |
| roxadustat | Astellas Pharma | Phase 3 | 77 |
| FK949E | Astellas Pharma | Phase 1 | 33 |